Results of aggressive chemotherapy for XXXX in adults.

@entity1 @entity5699 @entity229 @entity332 @entity2592 @entity3052 @entity1891 @entity204
Sixty-five @entity1 with @entity3052 , ranging in age from 16 to 73 years (median, 54), were treated with @entity332 , @entity2592 , @entity5699 , @entity229 , and @entity1891 to induce complete remission. Remission was maintained with monthly 5-day courses of @entity2592 and @entity332 for 4 years. Of the entire group, 57% achieved complete remission and 29% died in the first 30 days of treatment. The median remission duration was 15 months, with 20% of the complete responders predicted to remain in complete remission for 4 years. No primary central nervous system relapses have occurred. Of six variables examined by multivariate analysis, only age was predictive of remission success. Before analysis, the @entity1 were divided into groups by age: group 1--ages 16-42 years (n = 17); group 2--ages 43-59 years (n = 25); and group 3--ages 60-73 years (n = 23). Complete remission rates were 76% in group 1, 64% in group 2, and 35% in group 3 (P = 0.002). Lower remission rates for older @entity1 resulted from more early deaths rather than resistant disease. Age and LDH levels affected remission duration. The median complete remission duration was 48 months in group 1 and 10 months in groups 2 and 3 (P = 0.004). In group 1, 41% of @entity1 achieving complete remission are predicted to remain in complete remission for 4 years. We concluded that this five-drug induction regimen is highly effective for induction therapy in younger adults with @entity3052 . The results in @entity1 greater than or equal to 60 years of age are less satisfactory due to a lower remission rate and greater chance of @entity204 . Furthermore, these results demonstrate that the program as described results in a longer duration of complete remission for @entity1 of younger age.
